Michael D. Masinick

Array ( [id] => 18420142 [patent_doc_number] => 20230174603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => A PROTEIN COMPLEX COMPRISING AN IMMUNOCYTOKINE [patent_app_type] => utility [patent_app_number] => 17/916460 [patent_app_country] => US [patent_app_date] => 2021-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25032 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17916460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18552160 [patent_doc_number] => 20230250169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => AXL Inhibitors for Antiviral Therapy [patent_app_type] => utility [patent_app_number] => 17/995737 [patent_app_country] => US [patent_app_date] => 2021-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34452 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18365449 [patent_doc_number] => 20230147040 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => METHOD FOR PROGNOSIS PREDICTION OF SKIN CANCER AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/918704 [patent_app_country] => US [patent_app_date] => 2021-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9747 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17918704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418527 [patent_doc_number] => 20240294650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => ANTI-MERTK ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/995189 [patent_app_country] => US [patent_app_date] => 2021-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38352 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955200 [patent_doc_number] => 20240043527 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => RNA COMPOSITIONS TARGETING CLAUDIN-18.2 [patent_app_type] => utility [patent_app_number] => 17/915567 [patent_app_country] => US [patent_app_date] => 2021-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54855 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17915567 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17095433 [patent_doc_number] => 20210283224 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN [patent_app_type] => utility [patent_app_number] => 17/208409 [patent_app_country] => US [patent_app_date] => 2021-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22094 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17208409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200167 [patent_doc_number] => 20210340262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => DUAL RECEPTOR ANTAGONISTIC ANTIGEN-BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/205144 [patent_app_country] => US [patent_app_date] => 2021-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21742 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17205144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16932467 [patent_doc_number] => 20210198356 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => USE OF IL-1 BETA BINDING ANTIBODIES TO TREAT PERIPHERAL ARTERIAL DISEASE [patent_app_type] => utility [patent_app_number] => 17/204622 [patent_app_country] => US [patent_app_date] => 2021-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11623 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17204622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18345973 [patent_doc_number] => 20230134083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS [patent_app_type] => utility [patent_app_number] => 17/911347 [patent_app_country] => US [patent_app_date] => 2021-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -121 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17911347 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19916214 [patent_doc_number] => 12291567 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof [patent_app_type] => utility [patent_app_number] => 17/198229 [patent_app_country] => US [patent_app_date] => 2021-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 21 [patent_no_of_words] => 17324 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17198229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18637363 [patent_doc_number] => 11761956 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-19 [patent_title] => Nanopore biosensors for detection of proteins and nucleic acids [patent_app_type] => utility [patent_app_number] => 17/196810 [patent_app_country] => US [patent_app_date] => 2021-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 59 [patent_no_of_words] => 19164 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17196810 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18294854 [patent_doc_number] => 20230104540 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => USE OF ANTI-FAM19A1 ANTAGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES [patent_app_type] => utility [patent_app_number] => 17/905453 [patent_app_country] => US [patent_app_date] => 2021-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51143 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -97 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067281 [patent_doc_number] => 20210269496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => TISSUE TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR [patent_app_type] => utility [patent_app_number] => 17/178926 [patent_app_country] => US [patent_app_date] => 2021-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47760 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17178926 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18962906 [patent_doc_number] => 11896645 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions [patent_app_type] => utility [patent_app_number] => 17/177614 [patent_app_country] => US [patent_app_date] => 2021-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 36 [patent_no_of_words] => 21717 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17177614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17044950 [patent_doc_number] => 11098118 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-24 [patent_title] => Anti-claudin 18.2 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/176820 [patent_app_country] => US [patent_app_date] => 2021-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 19 [patent_no_of_words] => 24783 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17176820 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17368370 [patent_doc_number] => 20220023422 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/172490 [patent_app_country] => US [patent_app_date] => 2021-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13700 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17172490 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18777876 [patent_doc_number] => 11819552 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-21 [patent_title] => Antibody-drug conjugates targeting uPARAP [patent_app_type] => utility [patent_app_number] => 17/166177 [patent_app_country] => US [patent_app_date] => 2021-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 19 [patent_no_of_words] => 15242 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 301 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17166177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18270073 [patent_doc_number] => 20230091315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => ANTI-G-PROTEIN ALPHA ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/796375 [patent_app_country] => US [patent_app_date] => 2021-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14967 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17796375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19043607 [patent_doc_number] => 11932691 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-19 [patent_title] => Anti-ROR1 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/157810 [patent_app_country] => US [patent_app_date] => 2021-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 22575 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 194 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17157810 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18212225 [patent_doc_number] => 20230058489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => COMBINATION COMPRISING A TIM-3 INHIBITOR AND A HYPOMETHYLATING AGENT FOR USE IN TREATING MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA [patent_app_type] => utility [patent_app_number] => 17/758671 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50213 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17758671 [rel_patent_id] =>[rel_patent_doc_number] =>)